Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Claggett

Showing results (311-320 of 362) with videos related to

Pageof 37
Sort By:
American Heart Journal|May 13, 2015
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placeboRhonda Bentley-Lewis, David Aguilar, Matthew C Riddle, et al.
Circulation. Heart Failure|November 16, 2024
Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical TrialsPablo M Marti-Castellote, Christopher Reeder, Brian Claggett, et al.
Circulation|October 15, 2020
Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial InfarctionDaniel Modin, Brian Claggett, Caroline Sindet-Pedersen, et al.
Journal of the American College of Cardiology|February 28, 2024
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMIDouglas L Mann, Johny Nicolas, Brian Claggett, et al.
European Journal of Heart Failure|December 18, 2024
Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial dataOffer Amir, Gabby Elbaz-Greener, Shemy Carasso, et al.
JACC. Heart Failure|September 2, 2025
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy -Primary results of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients (ENVAD-HF)Maja Cikes, Jasper J Brugts, Brian Claggett, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
JAMA Cardiology|January 24, 2024
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER TrialOrly Vardeny, Akshay S Desai, Pardeep S Jhund, et al.
Journal of Cardiac Failure|January 12, 2024
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF StudyG Michael Felker, Scott D Solomon, Marco Metra, et al.
European Journal of Heart Failure|December 15, 2024
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HFXiaowen Wang, Orly Vardeny, Brian Claggett, et al.
Pageof 37

Showing results (311-320 of 362) with videos related to

Sort By:
Pageof 37
American Heart Journal|May 13, 2015
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placeboRhonda Bentley-Lewis, David Aguilar, Matthew C Riddle, et al.
Circulation. Heart Failure|November 16, 2024
Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical TrialsPablo M Marti-Castellote, Christopher Reeder, Brian Claggett, et al.
Circulation|October 15, 2020
Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial InfarctionDaniel Modin, Brian Claggett, Caroline Sindet-Pedersen, et al.
Journal of the American College of Cardiology|February 28, 2024
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMIDouglas L Mann, Johny Nicolas, Brian Claggett, et al.
European Journal of Heart Failure|December 18, 2024
Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial dataOffer Amir, Gabby Elbaz-Greener, Shemy Carasso, et al.
JACC. Heart Failure|September 2, 2025
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy -Primary results of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients (ENVAD-HF)Maja Cikes, Jasper J Brugts, Brian Claggett, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
JAMA Cardiology|January 24, 2024
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER TrialOrly Vardeny, Akshay S Desai, Pardeep S Jhund, et al.
Journal of Cardiac Failure|January 12, 2024
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF StudyG Michael Felker, Scott D Solomon, Marco Metra, et al.
European Journal of Heart Failure|December 15, 2024
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HFXiaowen Wang, Orly Vardeny, Brian Claggett, et al.
Pageof 37